Status:
UNKNOWN
Efficacy and Safety of Precision Therapy in Refractory Tumor
Lead Sponsor:
Baodong Qin
Conditions:
Rare Tumor
Refractory Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor aft...
Detailed Description
The individuals recruited in the present study are with solid tumor, mainly including two parts: first, rare tumor without standard recommended treatment such as atypical fibrous histiocytoma; second,...
Eligibility Criteria
Inclusion
- Malignant solid tumors diagnosed histologically;
- Common solid tumor patients have no any standard choice after multiple line of therapy; Rare solid tumor did not have any standard recommended treatment;
- Expected survival ≥ 1 month;
- ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL \<1.5 times the upper limit of normal (ULN); Liver ALT and AST \<2.5 × ULN and if liver metastases, ALT and AST \<5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min
Exclusion
- Patient still has standard treatment therapy based on NCCN guidance;
- Patient can not comply with research program requirements or follow-up;
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03239015
Start Date
January 1 2017
End Date
December 31 2023
Last Update
March 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China, 200003